Cargando…
Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study
BACKGROUND: Immunogenicity of tumor necrosis factor alpha inhibitors (TNFis) has been recognized as an important problem that may cause loss of efficacy and adverse events such as infusion reactions. TNFis are being increasingly used among patients with Behçet syndrome (BS) and scarce data exist on...
Autores principales: | Esatoglu, Sinem Nihal, Akkoc-Mustafayev, Fatma Nihan, Ozguler, Yesim, Ozbakır, Fatma, Nohut, Okan K., Cevirgen, Dilsen, Hamuryudan, Vedat, Hatemi, Ibrahim, Celik, Aykut Ferhat, Yazici, Hasan, Hatemi, Gulen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782473/ https://www.ncbi.nlm.nih.gov/pubmed/33414791 http://dx.doi.org/10.3389/fimmu.2020.618973 |
Ejemplares similares
-
Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behcet's Syndrome: A Strobe-Compliant Observational Study From a Dedicated Multidisciplinary Center
por: Hatemi, Ibrahim, et al.
Publicado: (2016) -
Recent Insights into the Management of Behçet Syndrome
por: Ozguler, Yesim, et al.
Publicado: (2021) -
Behçet’s syndrome: providing integrated care
por: Esatoglu, Sinem Nihal, et al.
Publicado: (2017) -
Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists
por: Hatemi, Gulen, et al.
Publicado: (2012) -
The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet’s syndrome
por: Ozcifci, Guzin, et al.
Publicado: (2021)